Contract Manufacturers

AsymBio to secure $184m to support growth in biologics manufacturing

Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.

Resilience and Lilly to increase US medicines production with $750m investment

Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of Lilly’s KwikPen injectable device in Ohio, aiming to strengthen the supply of diabetes and obesity medicines in the US.

Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

Intravac signs licensing deal with Zhifei Lvzhu for whooping cough vaccine

Intravacc has signed an exclusive licensing agreement with Beijing Zhifei Lvzhu Biopharmaceutical (Zhifei Lvzhu) in China for Avacc 3, an OMV-based whooping cough vaccine.

Sanofi to manufacture 125 million doses of Pfizer-BioNTech’s Covid-19 vaccine

French pharma giant Sanofi has entered into an agreement with BioNTech, to manufacture the Covid-19 vaccine co-developed by BioNTech and Pfizer.

Thermo Fisher Scientific acquires viral vector business from Novasep for $875m

Thermo Fisher Scientific announced the acquisition of Henogen, a Belgian viral vector manufacturing business belonging to Groupe Novasep, for about €725m ($875m) in cash.